Celsion Corp

Find Ratings Reports
CLSN : NASDAQ : Health Care
$0.389 | %
Today's Range: 0.0 - 0.0
Avg. Daily Volume: 724700.0
01/23/17 - 4:00 PM ET

Financial Analysis


CELSION CORP's gross profit margin for the third quarter of its fiscal year 2016 has significantly decreased when compared to the same period a year ago. While net income decreased, sales have remained unchanged. CELSION CORP has weak liquidity. Currently, the Quick Ratio is 0.89 which shows a lack of ability to cover short-term cash needs. The company's liquidity has decreased from the same period last year.

At the same time, stockholders' equity ("net worth") has significantly decreased by 57.85% from the same quarter last year. Overall, the key liquidity measurements indicate that the company is in a position in which financial difficulties could develop in the future.

STOCKS TO BUY: TheStreet Quant Ratings has identified a handful of stocks that can potentially TRIPLE in the next 12-months. To learn more visit www.TheStreetRatings.com.



Income Statement Q3 FY16 Q3 FY15
Net Sales ($mil)0.130.13
EBITDA ($mil)-5.48-4.13
EBIT ($mil)-5.6-4.24
Net Income ($mil)-6.41-4.27


Balance Sheet Q3 FY16 Q3 FY15
Cash & Equiv. ($mil)8.724.35
Total Assets ($mil)37.4653.66
Total Debt ($mil)3.597.32
Equity ($mil)10.5725.08


Profitability Q3 FY16 Q3 FY15
Gross Profit Margin-4380.0-3305.6
EBITDA Margin-4380.0-3305.6
Operating Margin-4477.6-3393.6
Sales Turnover0.010.01
Return on Assets-59.18-43.61
Return on Equity-209.71-93.3
Debt Q3 FY16 Q3 FY15
Current Ratio0.922.94
Debt/Capital0.250.23
Interest Expense0.160.32
Interest Coverage-34.76-13.13


Share Data Q3 FY16 Q3 FY15
Shares outstanding (mil)26.0623.03
Div / share0.00.0
EPS-0.23-0.19
Book value / share0.411.09
Institutional Own % n/a n/a
Avg Daily Volume711423.093179.0

Valuation


SELL. The current P/E ratio is negative, which has no meaningful value in the assessment of premium or discount valuation, it simply displays that the company has negative earnings. For additional comparison, its price-to-book ratio of 1.01 indicates a significant discount versus the S&P 500 average of 2.83 and a significant discount versus the industry average of 11.23. The price-to-sales ratio is well above the S&P 500 average, but well below the industry average. After reviewing these and other key valuation criteria, CELSION CORP proves to trade at a discount to investment alternatives within the industry.


Price/Earnings
1 2 3 4 5
premium   discount
  Price/Cash Flow
1 2 3 4 5
premium   discount
CLSN NM Peers 33.71   CLSN NM Peers 26.76

Neutral. The absence of a valid P/E ratio happens when a stock can not be valued on the basis of a negative stream of earnings.

CLSN's P/E is negative making this valuation measure meaningless.

 

Neutral. The P/CF ratio, a stock’s price divided by the company's cash flow from operations, is useful for comparing companies with different capital requirements or financing structures.

CLSN's P/CF is negative making the measure meaningless.

 
Price/Projected
Earnings
1 2 3 4 5
premium   discount
  Price to
Earnings/Growth
1 2 3 4 5
premium   discount
CLSN NM Peers 24.59   CLSN NA Peers 0.40

Neutral. The absence of a valid price-to-projected earnings ratio happens when a stock can not be valued on the basis of a negative expected future earnings.

CLSN's ratio is negative making this valuation measure meaningless.

 

Neutral. The PEG ratio is the stock’s P/E divided by the consensus estimate of long-term earnings growth. Faster growth can justify higher price multiples.

Ratio not available.

 
Price/Book
1 2 3 4 5
premium   discount
  Earnings Growth
1 2 3 4 5
lower   higher
CLSN 1.01 Peers 11.23   CLSN 20.36 Peers 4.03

Discount. A lower price-to-book ratio makes a stock more attractive to investors seeking stocks with lower market values per dollar of equity on the balance sheet.

CLSN is trading at a significant discount to its peers.

 

Higher. Elevated earnings growth rates can lead to capital appreciation and justify higher price-to-earnings ratios.

CLSN is expected to have an earnings growth rate that significantly exceeds its peers.

 
Price/Sales
1 2 3 4 5
premium   discount
  Sales Growth
1 2 3 4 5
premium   discount
CLSN 21.37 Peers 131.67   CLSN 0.00 Peers 548.88

Discount. In the absence of P/E and P/B multiples, the price-to-sales ratio can display the value investors are placing on each dollar of sales.

CLSN is trading at a significant discount to its industry on this measurement.

 

Neutral. Comparing a company's sales growth to its industry helps to determine if the company is adding or losing market share.

The growth rate for CLSN is not available.

 

 

Latest Stock Upgrades/Downgrades